

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Horizon Health Limited

諾輝健康

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6606)

**RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR;
COMPLIANCE WITH RULES 3.10(1), 3.25, 3.27A and 13.92(2);
AND
CONTINUED SUSPENSION OF TRADING**

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS

The board (the “**Board**”) of directors (the “**Directors**”, and each a “**Director**”) of New Horizon Health Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Ms. KONG Jiangnan (“**Ms. KONG**”) has tendered her resignation as an independent non-executive Director, the chairman of the remuneration committee of the Board (the “**Remuneration Committee**”), a member of the nomination committee of the Board (the “**Nomination Committee**”), and a member of the independent special committee of the Company with effect from August 8, 2025 to devote more time to her other commissions and support an orderly transition of the Company.

Ms. KONG will not hold any position in the Group upon her resignation. Ms. KONG has confirmed that she has no disagreement with the Board or the management of the Company, and there are no other matters relating to her resignation that need to be brought to the attention of the Company’s shareholders or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its gratitude and appreciation to Ms. KONG for her contribution to the Company during her tenure of service.

COMPLIANCE WITH RULES 3.10(1), 3.25, 3.27A AND 13.92(2)

According to Rules 3.10(1), 3.25 and 3.27A of the Rules of Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”), (i) the Board must include at least three independent non-executive Directors; (ii) the Remuneration Committee must be chaired by an independent non-executive Director and comprise a majority of independent non-executive Directors; and (iii) the Nomination Committee must comprise a majority of independent non-executive Directors. In addition, Rule 13.92(2) requires the Company to immediately publish an announcement containing the relevant details and reasons if it is unable to have Directors of different genders on the Board.

Upon resignation of Ms. KONG, the Board comprises four male Directors, among whom only two are independent non-executive Directors. Furthermore, the Remuneration Committee does not have a chairman, and each of the Remuneration Committee and the Nomination Committee does not have a majority of independent non-executive Directors.

The Company is endeavoring to identify a suitable candidate to be appointed as an independent non-executive Director and fill the associated vacancies as soon as practicable, and will make further announcement(s) as and when appropriate.

CONTINUED SUSPENSION OF TRADING

Trading in the Company’s shares on the Stock Exchange has been suspended since March 28, 2024 and will remain suspended until further notice.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

For and on behalf of
New Horizon Health Limited
(Joint Provisional Liquidators Appointed)
Lai Wing Lun (Johnathan),
Osman Mohammed Arab
and Martin Nicholas John Trott
Joint Provisional Liquidators
Acting as agents without personal liability

Hong Kong, August 8, 2025

As at the date of this announcement, the Board comprises Mr. Naxin YAO as the Chairman and non-executive Director, Dr. Yiyou CHEN as executive Director, and Mr. Danke YU and Dr. Yang WANG as independent non- executive Directors.